W
WAVEMAN · COMPANY
BMRA · Biomerica Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

BMRA

BIOMERICA INC
PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0000073290
CLUSTER · 5 INSIDERSACTIVIST 13DC-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$158.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
5
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
10
13F, latest reported quarter
REVENUE GROWTH
-16.2%
XBRL, annual
NET MARGIN
-84.8%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$158.0K over 180 days
+$158.0K over 90 days
more than 79% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
10 funds added or opened last quarter
below 82% of Pharma & Biotech
REVENUE
-16.2% year over year
below 73% of Pharma & Biotech
MARGIN
-84.8% net margin
below 63% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
0.5% of shares outstanding short · 3.6 days to cover · settled 2026-07-31
below 78% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
5 insiders independently bought a net $158.0K — no planned sales are queued against it.
BRC Group Holdings, Inc. disclosed a 5%+ stake (10.03%) in the last six months.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -23.0%
-23.0%12M
-50%-31%-12%+7%2025-092025-102025-122026-032026-052026-072026-09 2026-08-26 · Irani Zackary S. bought $50.0K2026-08-20 · Gary M. Huff bought $50.0K2026-08-26 · BARBIERI ALLEN bought $32.0K2026-08-26 · MOATAZEDI DAVID bought $16.0K2026-08-26 · Chin Eric bought $10.0K2026-08-28 · BRC Group Holdings, Inc. filed a 5%+ stake (10.03%)2026-08-28 · B. Riley Principal Capital, LLC filed a 5%+ stake (10.03%)2026-08-28 · Bryant R. Riley filed a 5%+ stake (10.03%)
INSIDER BUY13D/G STAKE
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
5 insiders reported buying shares.
The record shows a net $158.0K bought by insiders over 180 days, 10 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BIOMERICA INC insiders bought a net $158.0K of stock across 18 Form 4 purchases and sales, with 5 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
BARBIERI ALLEN
Executive Vice Chairman
BUY
2026-08-26
20,000.0
$32.0K
Irani Zackary S.
Chief Executive Officer
BUY
2026-08-26
31,250.0
$50.0K
MOATAZEDI DAVID
Director
BUY
2026-08-26
10,000.0
$16.0K
Chin Eric
Director
BUY
2026-08-26
6,250.0
$10.0K
Gary M. Huff
Director
BUY
2026-08-20
31,250.0
$50.0K
18 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 13 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
GEODE CAPITAL MANAGEMENT, LLC
24,347.0 sh
$42.9K
BlackRock, Inc.
18,636.0 sh
$32.8K
VANGUARD CAPITAL MANAGEMENT LLC
14,514.0 sh
$25.5K
JANE STREET GROUP, LLC
12,640.0 sh
$22.2K
LPL Financial LLC
10,849.0 sh
$19.1K
5%+ owners
13D = intent to influence · 13G = passive
BRC Group Holdings, Inc.
ACTIVIST 13D · 2026-08-28
10.03%
B. Riley Principal Capital, LLC
ACTIVIST 13D · 2026-08-28
10.03%
Bryant R. Riley
ACTIVIST 13D · 2026-08-28
10.03%
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Extended Market Index Fund
$24.6K POSITION · AS OF 2026-02-28
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$30.6K POSITION · AS OF 2026-03-31
0.0%
Fidelity Series Total Market Index Fund
$7.3K POSITION · AS OF 2026-02-28
0.0%
Fidelity Total Market Index Fund
$3.6K POSITION · AS OF 2026-02-28
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release
1
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Zackary Irani
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2024
$201.0K
$177.7K
$219.8K
-89%
—
2023
$360.1K
$199.8K
$314.8K
-83%
—
2022
$141.2K
-$108.4K
$174.0K
-61%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2026-052025-052024-052023-05
REVENUE$4.5M$5.3M$5.4M$5.3M
GROSS PROFIT$362.0K$498.0K$611.0K$446.0K
OPERATING INCOME$-5.3M$-5.1M$-6.4M$-7.2M
NET INCOME$-3.8M$-5.0M$-6.0M$-7.1M
EPS (DILUTED)-1.30-2.16-2.84-0.50
OPERATING CASH FLOW$-3.4M$-3.8M$-5.4M$-5.5M
CASH$1.3M$2.4M$4.2M$9.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →